Nautilus Biotechnology develops the Voyager single-molecule proteomics platform that uses iterative mapping to detect and count individual proteins and proteoforms with high sensitivity and scale. The technology is intended to expand access to detailed proteome information for advancing drug discovery and understanding disease mechanisms. The company supplies the associated hardware, reagents, and software to research partners and institutions.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -15 | — |
| Q3 2025 | 0 | — | -13.6 | — |
| Q4 2025 | 0 | — | -13.8 | — |
| Q1 2026 | 0 | — | -14.7 | — |
| Q2 2026 | 0 | — | -14.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: FACT II Acquisition Corp (FACT), Perma-Fix Environmental Services, Inc. (PESI), Newbury Street II Acquisition Corp (NTWO), Prelude Therapeutics Incorporated (PRLD), TRG Latin America Acquisitions Corp. (TRGS), Omega Flex, Inc. (OFLX)